Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis

Authors: Run Hu, Jie Xu, Hongxiang Wang, Jiaguo Wang, Kai Lei, Xiaoping Zhao, Huizhi Zhang, Ke You, Zuojin Liu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The purpose of this propensity score matching (PSM) analysis was to compare the effects of preoperative transcatheter arterial chemoembolization (TACE) and non-TACE on the long-term survival of patients who undergo radical hepatectomy.

Methods

PSM analysis was performed for 387 patients with hepatocellular carcinoma (HCC) (single > 3 cm or multiple) who underwent radical resection of HCC at our centre from January 2011 to June 2018. The patients were allocated to a preoperative TACE group (n = 77) and a non-TACE group (n = 310). The main outcome measures were progression-free survival (PFS) and overall survival (OS) since the treatment date.

Results

After PSM, 67 patients were included in each of the TACE and non-TACE groups. The median PFS times in the preoperative TACE and non-TACE groups were 24.0 and 11.3 months, respectively (p = 0.0117). The median OS times in the preoperative TACE and non-TACE groups were 41.5 and 29.0 months, respectively (p = 0.0114). Multivariate Cox proportional hazard regression analysis revealed that preoperative TACE (hazard ratio, 1.733; 95% CI, 1.168–2.570) and tumour thrombosis (hazard ratio, 0.323; 95% CI, 0.141–0.742) were independent risk factors significantly associated with OS.

Conclusions

Preoperative TACE is related to improving PFS and OS after resection of HCC. Preoperative TACE and tumour thrombus volume were also found to be independent risk factors associated with OS.
Literature
1.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.CrossRefPubMed
2.
Shimozawa N, Hanazaki K. Longterm prognosis after hepatic resection for small hepatocellular carcinoma. J Am Coll Surg. 2004;198(3):356–65.CrossRefPubMed
3.
Ahn KS, Kang KJ. Appropriate treatment modality for solitary small hepatocellular carcinoma: radiofrequency ablation vs. resection vs. Transplantation? Clin Mol Hepatol. 2019;25(4):354–9.CrossRefPubMed
4.
Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019;70(5):866–73.CrossRefPubMed
5.
Xu X-L, Liu X-D, Liang M, Luo B-M. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology. 2018;287(2):461–72.CrossRefPubMed
6.
Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20(3):130–40.CrossRefPubMed
7.
Kanwal F, Befeler A, Chari RS, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, Schwartz J, et al. Potentially curative treatment in patients with hepatocellular cancer–results from the liver cancer research network. Aliment Pharmacol Ther. 2012;36(3):257–65.CrossRefPubMed
8.
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–55.CrossRefPubMed
9.
Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187–95.CrossRefPubMed
10.
Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, Yoo BC. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2010;16(4):383–8.CrossRefPubMedPubMedCentral
11.
Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, Wu MC. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249(2):195–202.CrossRefPubMed
12.
Kobayashi T, Teruya M. Preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2010;251(2):386. author reply 386–387.CrossRefPubMed
13.
Lee KT, Lu YW, Wang SN, Chen HY, Chuang SC, Chang WT, Shi HY, Ker CG, Chiu HC. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol. 2009;99(6):343–50.CrossRefPubMed
14.
Kim IS, Lim YS, Lee HC, Suh DJ, Lee YJ, Lee SG. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome. Aliment Pharmacol Ther. 2008;27(4):338–45.CrossRefPubMed
15.
Sasaki A, Iwashita Y, Shibata K, Ohta M, Kitano S, Mori M. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol. 2006;32(7):773–9.CrossRefPubMed
16.
Kaibori M, Tanigawa N, Matsui Y, Saito T, Uchida Y, Ishizaki M, Tanaka H, Kamiyama Y. Influence of transcatheter arterial chemoembolization on the prognosis after hepatectomy for hepatocellular carcinoma in patients with severe liver dysfunction. Anticancer Res. 2006;26(5B):3685–92.PubMed
17.
Choi G-H, Kim D-H, Kang C-M, Kim K-S, Choi J-S, Lee W-J, Kim B-R. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg. 2007;31(12):2370–7.CrossRefPubMed
18.
Shi H-Y, Wang S-N, Wang SC, Chuang S-C, Chen C-M, Lee K-T. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors. J Surg Oncol. 2014;109(5):487–93.CrossRefPubMed
19.
Ha T-Y, Hwang S, Lee Y-J, Kim K-H, Ko G-Y, Ii Gwon D, Ahn C-S, Moon D-B, Song G-W, Jung D-H, et al. Absence of benefit of transcatheter arterial chemoembolization (TACE) in patients with resectable solitary hepatocellular carcinoma. World J Surg. 2016;40(5):1200–10.CrossRefPubMed
20.
Chen X-p, Zhang HD-y, Zhang Z-w, Chen B-x. Zhang W-g, Qiu F-z. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Dig Surg. 2007;24(3):208–13.CrossRefPubMed
21.
Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer. 2000;89(12):2606–12.CrossRefPubMed
22.
Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30(2):166–74.CrossRefPubMed
23.
Wang X, Yuan Y, Wang J, Liu Z, Chen M, Zhou Q, Zhou Z. Preoperative versus postoperative transarterial chemoembolization on prognosis of large hepatocellular carcinoma. J Cancer. 2021;12(20):6231–41.CrossRefPubMedPubMedCentral
24.
Kaibori M, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J, Koreeda C, Seki T, Sawada S, Okazaki K, et al. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci. 2012;57(5):1404–12.CrossRefPubMed
25.
Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol. 2013;42(1):151–60.CrossRefPubMed
26.
Zhang Y-F, Guo R-P, Zou R-H, Shen J-X, Wei W, Li S-H, OuYang H-Y, Zhu H-B, Xu L, Lao X-M, et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol. 2016;26(7):2078–88.CrossRefPubMed
27.
28.
Yang Y, Lin K, Liu L, Qian Y, Yang Y, Yuan S, Zhu P, Huang J, Liu F, Gu F, et al. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: a propensity score matching analysis. Cancer Med. 2021;10(6):2100–11.CrossRefPubMedPubMedCentral
29.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–16.CrossRefPubMed
30.
Lu J, Zhao M, Arai Y, Zhong B-Y, Zhu H-D, Qi X-L, de Baere T, Pua U, Yoon HK, Madoff DC, et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of international society of multidisciplinary interventional oncology (ISMIO). Hepatobiliary Surg Nutr. 2021;10(5):661–71.CrossRefPubMedPubMedCentral
31.
Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018;53(6):1112–7.CrossRefPubMed
32.
Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234(1):71–8.CrossRefPubMedPubMedCentral
33.
Lim KC, Chow PKH, Allen JC, Siddiqui FJ, Chan ESY, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012;99(12):1622–9.CrossRefPubMed
34.
Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011(3):CD004787.
35.
Xiao E, Li D, Shen S, Zhou S, Tan L, Wang Y, Luo J, Wu Y, Tan C, Liu H, et al. Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells. Chin Med J (Engl). 2003;116(2):203–7.PubMed
36.
Lu W, Li Y-H, He X-F, Mo Y-Y, Zhu Z-Y. Transcatheter arterial chemoembolization enhances expression of Nm23-H1 and TIMP-2 in the tumor tissue of patients with hepatocellular carcinoma. Hepatogastroenterology. 2011;58(106):558–64.PubMed
37.
Ren Z, Yue Y, Zhang Y, Dong J, Liu Y, Yang X, Lin X, Zhao X, Wei Z, Zheng Y, et al. Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles. Front Immunol. 2021;12:624789.CrossRefPubMedPubMedCentral
38.
Cong W-M, Bu H, Chen J, Dong H, Zhu Y-Y, Feng L-H, Chen J. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–87.CrossRefPubMedPubMedCentral
39.
Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004;139(7):766–74.CrossRefPubMed
40.
Zhang C-W, Dou C-W, Zhang X-L, Liu X-Q, Huang D-S, Hu Z-M, Liu J. Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy. World J Gastroenterol. 2020;26(30):4489–500.CrossRefPubMedPubMedCentral
41.
Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, Konno T, Iwamoto S, Ohnishi K, Okuda K. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985;154(1):19–24.CrossRefPubMed
Metadata
Title
Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis
Authors
Run Hu
Jie Xu
Hongxiang Wang
Jiaguo Wang
Kai Lei
Xiaoping Zhao
Huizhi Zhang
Ke You
Zuojin Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11978-4

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma

Research

Health-related risk behaviors among U.S. childhood cancer survivors: a nationwide estimate

Research

ESCO2’s oncogenic role in human tumors: a pan-cancer analysis and experimental validation

Research

Development and validation of a novel preoperative clinical model for predicting lymph node metastasis in perihilar cholangiocarcinoma

Research

Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28

Editorial

Advances in personalized radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits